Pitcairn’s Cidara Therapeutics CDTX Stock Holding History

Pitcairn’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,158	Closed	-$47K	–	622
2021 Q2	$47K	Buy	+1,158	New	+$49K	﹤0.01%	610

Other funds holding CDTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Pitcairn's CDTX Position: Q3 2021 in Review

Pitcairn sold out of Cidara Therapeutics (CDTX) in Q3 2021, closing a stake of 1,158 shares — an estimated $47K sold.

Pitcairn first reported a position in CDTX in Q2 2021 and held it in 1 quarter. The position peaked at $47K in Q2 2021. 50 funds tracked by Wall St. Rank hold CDTX as of Q3 2021.

Pitcairn reported no remaining Cidara Therapeutics position as of Q3 2021 after selling out during the quarter.
Pitcairn sold 1,158 Cidara Therapeutics shares in Q3 2021, an estimated $47K.
Pitcairn first reported a position in Cidara Therapeutics in Q2 2021 and held it in 1 quarter.
Pitcairn's Cidara Therapeutics position peaked at $47K in Q2 2021.
50 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2021.

Based on Pitcairn's 13F filing for Q3 2021, filed 10 Nov 2021.